<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02998437</url>
  </required_header>
  <id_info>
    <org_study_id>IY81149-DI03</org_study_id>
    <nct_id>NCT02998437</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole</brief_title>
  <acronym>DDI</acronym>
  <official_title>A Randomized, Open-label, Parallel-design Study to Evaluate Pharmacokinetic Drug Interactions and Safety After Coadministration of Clarithromycin, Amoxicillin and Ilaprazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Il-Yang Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Il-Yang Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the pharmacokinetic drug interaction in Ilaprazole, Clarithromycin,
      Amoxicillin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluate the pharmacokinetic drug interaction and safety in Ilaprazole,
      Clarithromycin, Amoxicillin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ilaprazole AUClast(Area Under the plasma concentration-time Curve at the last observed time point)</measure>
    <time_frame>Predose(0h), after dose 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ilaprazole Cmax(the maximum serum concentration)</measure>
    <time_frame>Predose(0h), after dose 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clarithromycin, Amoxicillin AUClast</measure>
    <time_frame>Predose(0h), after dose 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clarithromycin, Amoxicillin Cmax</measure>
    <time_frame>Predose(0h), after dose 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ilaprazole AUCinf(Area Under the plasma concentration-time Curve from time zero to infinity)</measure>
    <time_frame>Predose(0h), after dose 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ilaprazole Tmax(the time to reach Cmax)</measure>
    <time_frame>Predose(0h), after dose 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ilaprazole t1/2(the elimination half-life)</measure>
    <time_frame>Predose(0h), after dose 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ilaprazole CL/F(the oral clearance)</measure>
    <time_frame>Predose(0h), after dose 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ilaprazole Vd/F(apparent volume of distribution after non-intravenous administration)</measure>
    <time_frame>Predose(0h), after dose 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clarithromycin, Amoxicillin AUCinf</measure>
    <time_frame>Predose(0h), after dose 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clarithromycin, Amoxicillin Tmax</measure>
    <time_frame>Predose(0h), after dose 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clarithromycin, Amoxicillin t1/2</measure>
    <time_frame>Predose(0h), after dose 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clarithromycin, Amoxicillin CL/F</measure>
    <time_frame>Predose(0h), after dose 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clarithromycin, Amoxicillin Vd/F</measure>
    <time_frame>Predose(0h), after dose 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48h</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Drug Interaction Potentiation</condition>
  <arm_group>
    <arm_group_label>Ilaprazole 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Ilaprazole 10mg 1 tab.m one a day
Period 2: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap. twice a day, 6 days Ilaprazole 10mg, one a day at the 5 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clarithromycin 500mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day
Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at the 5 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin 500mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day
Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at 5 day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ilaprazole 10mg</intervention_name>
    <description>Period 1: Ilaprazole 10mg, one a day, one day Period 2: Ilaprazole 10mg, twice a day, 6 days</description>
    <arm_group_label>Ilaprazole 10mg</arm_group_label>
    <other_name>Noltec(the brand name)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin 500mg</intervention_name>
    <description>Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day</description>
    <arm_group_label>Clarithromycin 500mg</arm_group_label>
    <other_name>Klaricid 500mg(the brand name)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin 500 Mg</intervention_name>
    <description>Period 1: Amoxicillin 500mg 2 cap., one a day, one day Period 2: Amoxicillin 500mg 2 cap., one a day at 5 day</description>
    <arm_group_label>Amoxicillin 500mg</arm_group_label>
    <other_name>Amoxicillin Cap. 500mg Chongkundang(the brand name)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male adults aged ≥19 years and &lt;50 years at screening

          2. Body mass index ≥18.5 and &lt;25

               -  Body mass index (kg/m2) = body weight (kg)/[height (m)]2

          3. Men who have sexual relationship with women of child bearing potential must give
             consent to using contraceptive measures (condoms, spermicide, and menstrual cycle
             control) and avoiding sperm donation during the study and up to 28 days following the
             last dose of IMP (these contraceptive measures are not required if the male subject or
             female partner is infertile).

          4. Those who voluntarily decided to participate in this study and gave written consent to
             comply with the requirements after receiving sufficient explanation and fully
             understanding this study.

        Exclusion Criteria:

          1. Hypersensitivity or history of clinically significant hypersensitivity to active
             ingredients or excipients (in particular, Yellow No. 4 (Tartrazine); Yellow No. 5
             (Sunset Yellow FCF); macrolide antibiotics such as Clarithromycin and erythromycin; or
             Penicillins)

          2. History of QT prolongation or ventricular arrhythmia (including Torsadedes de pointes)

          3. Clinically significant, current or past disorder of hepatobiliary (severe hepatic
             impairment, etc.), renal (severe renal impairment, etc.), nervous, immune,
             respiratory, endocrine, blood•tumor, cardiovascular (heart failure, etc.), or
             psychiatric system

          4. History of gastrointestinal disorder (Crohn's disease, ulcer, etc.) or operation
             (excluding simple appendectomy or herniotomy) that may affect drug absorption

          5. Administration of other IMP from other study (including biological comparability test)
             within 3 months of the first dose of IMP.

          6. Whole blood donation within 60 days, or apheresis donation within 30 days before the
             first dose of IMP.

          7. Constant caffeine intake (&gt; 5 cups of coffee/day, &gt; 1250 cc of tea/day, &gt; 1250 cc of
             cola/day), constant smoking (more than 10 cigarettes/day) or constant alcohol drinking
             (more than 210 g/week) or inability to refrain from alcohol consumption from 2 days
             before the first dose of IMP until the end of PK assessment.

          8. Consumption of grapefruit-containing food within 7 days before the first dose of IMP

          9. History of drug abuse within 1 year before screening, or positive response in urine
             drug misuse/abuse screening test

         10. Use of medicinal products that are expected to or may affect the metabolism of IMP;
             St. John's wort; or relevant preparations within 30 days of IMP administration

         11. Use of following medicinal products within given time period excluding local
             preparations, which do not have significant systemic absorption, and hormonal
             contraceptives

               -  Prescription drug within 14 days of the first dose of IMP

               -  OTC including health supplements and vitamins within 7 days of the first dose of
                  IMP

               -  Medicinal products via depot injection or other implantations within 30 days of
                  the first dose of IMP (excluding contraceptives)

               -  Drug metabolizing enzyme inducer or inhibitor such as barbiturate within 30 days
                  before the first dose of IMP

         12. Stable vital sign measured in sitting position at screening: systolic blood pressure &gt;
             150 mmHg or &lt; 90 mmHg, diastolic blood pressure &gt; 100 mmHg or &lt; 50 mmHg, pulse rate &gt;
             110 bpm or &lt;40 bpm

         13. Following findings at screening

               -  Blood total bilirubin &gt; 1.5 x upper limit of normal

               -  Blood AST (SGOT), ALT (SGPT) &gt; 1.25 x upper limit of normal

               -  MDRD-estimated eGFR &lt; 60 mL/min/1.73m2 eGFR (estimated glomerular filtration
                  rate)(mL/min/1.73m2) = 175 x [serum creatinine (mg/dL)]-1.154 x [age
                  (years)]-0.203

               -  Positive serum test (hepatitis B, hepatitis C, HIV, syphilis)

         14. Those considered ineligible by the investigator due to other screening results or
             reasons.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min MS Park, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

